Although about half of CHF patients have a preserved EF, no meds have been shown to improve patient outcomes. This industry sponsored RCT of >4000 patients, age >60, with CHF and EF > 45% found no difference in mortality or cardiovascular hospitalization between those randomized to irbesartan or placebo (consistent across all measured subgroups) after mean f/u of >4 years. The irbesartan patients were more likely to have at least 1 measured doubling of creatinine. There is no clear role for ARBs in normal EF CHF (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]